Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and Physicians
Practical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.
The Evolving Landscape of Renal Cell Carcinoma Management
Healthcare professionals reflect on recent evolutions in the renal cell carcinoma treatment landscape.
Support Networks for Patients With Renal Cell Carcinoma
Panelists share their perspective on establishing a support network for patients undergoing treatment for renal cell carcinoma.
Managing Adverse Events While on Treatment for Renal Cell Carcinoma
Laura Sanza, PhD, MPAS, PA-C, leads a discussion on communicating adverse events with patients and mitigating potential toxicities.
Treatment Decision Making in RCC: Patient and Caregiver Perspectives
A brief discussion elucidating the patient and caregiver perspectives when selecting a treatment option for renal cell carcinoma.
Frontline Therapy for Non-Clear Cell RCC
The panel wraps up their discussion with a review of how they would approach treating frontline non-clear cell RCC.
Disease Progression After Adjuvant Pembrolizumab Therapy for RCC
The panel shares how they would treat a patient with advanced RCC after disease progression on adjuvant pembrolizumab.
Clinical Trials in Adjuvant IO Therapy for RCC
Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.
Treatment for RCC: Educating Patients on Followup and Adverse Events
Comprehensive insight on how best to communicate potential adverse events and followup strategies with patients going on therapy for RCC.
Renal Cell Carcinoma: Expert Perspectives on Treatment Selection
Hans Hammers, MD, PhD, provides a broad overview on the treatment options available to patient who receive a diagnosis of renal cell carcinoma.
Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC
The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.
COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC
The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.
Communicating a Diagnosis of RCC to Patients
Expert and patient perspectives on the communication that occurs leading up to and following a diagnosis of renal cell carcinoma.
Healthcare Professional Perspectives on Diagnosing RCC
Healthcare professionals contextualize Terri Blalock’s experience by highlighting the typical presentation of RCC and elucidating workup procedures used to confirm a diagnosis.
Approaches to Dosing TKIs in Patients with Advanced RCC
Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.
Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens
The panel discusses which patients they would consider switching between immunotherapy combination treatments.
Receiving a Diagnosis of RCC: Patient and Caregiver Perspectives
Shared insight from Terri Blalock and her caregiver, Kaitlin Blalock, regarding the diagnosis of renal cell carcinoma Terri received following a number of symptoms.
An Expert Overview of Renal Cell Carcinoma
Expert oncologist Hans Hammers, MD, PhD, spearheads an overview on renal cell carcinoma, covering its current incidence and known risk factors.
Approaches to the Frontline Treatment of Advanced Kidney Cancer
Experts summarize their most common frontline treatment approaches to advanced RCC.
Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy
Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.
Impact of the CLEAR Trial Data Updates in Clinical Practice
The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings
Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes
Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.
2 Commerce Drive Cranbury, NJ 08512